

Updated Notice of Distribution Model for Cometriq®

This notice provides information for 340B covered entities regarding the distribution of Cometriq® (cabozantinib):

Product	Form	Dosage	NDC	UPPS
COMETRIQ	Capsule	140 MG DAILY-DOSE PACK	42388-0011-14	112
COMETRIQ	Capsule	100 MG DAILY-DOSE PACK	42388-0012-14	56
COMETRIQ	Capsule	60 MG DAILY-DOSE PACK	42388-0013-14	84

Cometriq is an orphan drug approved to treat a very small patient population, and Exelixis therefore distributes Cometriq through an authorized network of specialty pharmacies and specialty distributors that are equipped to successfully facilitate patient care. Any customer may purchase Cometriq through this network. Those facilities (including 340B entities) that have an on-site pharmacy may acquire Cometriq through one of our specialty distributor partners. For any facility without an on-site pharmacy, Cometriq may be acquired through one of Exelixis' in-network specialty pharmacy partners. Exelixis' in-network specialty pharmacy and specialty distributor partners are as follows:

Specialty Pharmacies (U.S.)

- Accredo Specialty Pharmacy
- CVS Caremark Specialty Pharmacy
- Diplomat Specialty Pharmacy

Specialty Distributors for Institutions/Hospitals

- Cardinal Health Specialty Distribution
- McKesson Plasma and Biologics

Exelixis takes its obligations under the 340B program seriously and makes every effort to ensure that Cometriq is available to eligible 340B covered entities at the applicable statutory ceiling price, in a manner that is no more restrictive than it is for non-340B entities.

The distribution model described above is consistent with section 340B(a)(1) of the Public Health Service Act, which requires manufacturers to “offer each covered entity covered outpatient drugs for purchase at or below the applicable ceiling price if such drug is made available to any other purchaser at any price.”

If you have any questions regarding access to Cometriq, please contact Darnell Turner at 650-837-8155.